Data gathered: January 2
AI Stock Analysis - Arcutis Biotherapeutics (ARQT)
Analysis generated December 16, 2024. Powered by Chat GPT.
Arcutis Biotherapeutics is a leading biopharmaceutical company dedicated to developing novel treatments for dermatological conditions. With a strong focus on innovation and patient-centric care, the company aims to address unmet clinical needs in dermatology through its robust pipeline of drug candidates. Founded on scientific rigor and clinical expertise, Arcutis Biotherapeutics has been making strides in the therapeutic landscape, particularly in conditions like psoriasis and atopic dermatitis.
Stock Alerts - Arcutis Biotherapeutics (ARQT)
 |
Arcutis Biotherapeutics | January 2 Price is up by 5.3% in the last 24h. |
|
Arcutis Biotherapeutics | January 1 Insider Alert: Burnett Patrick is selling shares |
|
Arcutis Biotherapeutics | December 24 Insider Alert: Watanabe Todd Franklin is selling shares |
|
Arcutis Biotherapeutics | December 20 Price is up by 5.6% in the last 24h. |
Alternative Data for Arcutis Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 88 | Sign up | Sign up | Sign up |
| Google Trends | 5 | Sign up | Sign up | Sign up |
| Patents | 36 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 2,494 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,112 | Sign up | Sign up | Sign up |
| Twitter Followers | 554 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 48 | Sign up | Sign up | Sign up |
| Linkedin Employees | 356 | Sign up | Sign up | Sign up |
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
| Price | $14.56 |
| Target Price | Sign up |
| Volume | 2,460,000 |
| Market Cap | $1.63B |
| Year Range | $7.24 - $14.99 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Equities Analysts Offer Predictions for ARQT FY2024 EarningsJanuary 1 - ETF Daily News |
|
Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 1,691 Shares of StockJanuary 1 - ETF Daily News |
 |
Arcutis Biotherapeutics CMO Patrick Burnett sells shares for $23,674December 31 - Investing.com |
|
Arcutis Biotherapeutics (NASDAQ:ARQT) Coverage Initiated by Analysts at HC WainwrightDecember 30 - ETF Daily News |
|
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Todd Franklin Watanabe Sells 15,000 Shares of StockDecember 24 - ETF Daily News |
|
State Street Corp Boosts Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)December 20 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 45M | 64M | -20M | -42M | -38M | -0.330 |
| Q2 '24 | 31M | 62M | -31M | -52M | -50M | -0.420 |
| Q1 '24 | 50M | 58M | -8.7M | -35M | -27M | -0.320 |
| Q4 '23 | 14M | 58M | -52M | -66M | -58M | -0.720 |
| Q3 '23 | 38M | 236M | -205M | -45M | 154M | -0.730 |
Insider Transactions View All
| Burnett Patrick filed to sell 126,978 shares at $14. December 31 '24 |
| Watanabe Todd Franklin filed to sell 823,430 shares at $15.2. December 23 '24 |
| Welgus Howard G. filed to sell 161,944 shares at $12.5. December 3 '24 |
| Watanabe Todd Franklin filed to buy 838,430 shares at $7.1. December 3 '24 |
| Matsuda Masaru filed to buy 187,030 shares at $7.1. December 3 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Joshua Gottheimer Democrat |
Oct 15, 23 | Sell | $1K - $15K |
| Joshua Gottheimer Democrat |
May 19, 23 | Buy | $1K - $15K |
Read more about Arcutis Biotherapeutics (ARQT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Arcutis Biotherapeutics?
The Market Cap of Arcutis Biotherapeutics is $1.63B.
What is the current stock price of Arcutis Biotherapeutics?
Currently, the price of one share of Arcutis Biotherapeutics stock is $14.56.
How can I analyze the ARQT stock price chart for investment decisions?
The ARQT stock price chart above provides a comprehensive visual representation of Arcutis Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arcutis Biotherapeutics shares. Our platform offers an up-to-date ARQT stock price chart, along with technical data analysis and alternative data insights.
Does ARQT offer dividends to its shareholders?
As of our latest update, Arcutis Biotherapeutics (ARQT) does not offer dividends to its shareholders. Investors interested in Arcutis Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Arcutis Biotherapeutics?
Some of the similar stocks of Arcutis Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.